Literature DB >> 1429216

The andrology laboratory in an Assisted Reproductive Technologies program. Quality assurance and laboratory methodology.

C H Muller1.   

Abstract

Assuring the highest possible quality of care to the patient is the first goal of the andrology laboratory. Quality control and quality assurance as they apply to the andrology laboratory are outlined, and special problems in quality control for sperm function assays are addressed. An example of the patient review process is presented. Quality of care also depends on the ability of the laboratory to perform appropriate tests of sperm function that can diagnose sperm defects, predict success or failure of in vitro fertilization, and lead to rational therapies for sperm dysfunctions. Methods for, and diagnostic value of, sperm swim-out, enhanced sperm penetration assays, acrosome reaction assessment, motility analysis of capacitating sperm, and sperm-zona binding assays are reviewed. No single test, other than in vitro fertilization itself, is capable of providing a complete diagnosis or a highly accurate prediction. A battery of sperm function tests, arranged in an algorithm, is presented as a theoretically better approach.

Entities:  

Mesh:

Year:  1992        PMID: 1429216

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  3 in total

Review 1.  Male infertility: evaluation of human sperm function and its clinical application.

Authors:  A Lenzi
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

2.  Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility.

Authors:  Louise Hetherington; Elena K Schneider; Caroline Scott; David DeKretser; Charles H Muller; Hubert Hondermarck; Tony Velkov; Mark A Baker
Journal:  Mol Cell Proteomics       Date:  2016-10-21       Impact factor: 5.911

Review 3.  Phosphorylation of Izumo1 and Its Role in Male Infertility.

Authors:  Samantha A M Young; John Aitken; Mark A Baker
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.